Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
Liver Int ; 35(4): 1303-14, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25156780

RESUMO

BACKGROUND & AIMS: Branched-chain amino acids (BCAA) reduce the incidence of hepatocellular carcinoma (HCC) in patients with cirrhosis. However, the mechanisms that underlie these effects remain unknown. Previously, we reported that oxidative stress in male transgenic mice that expressed hepatitis C virus polyprotein (HCVTgM) caused hepatic iron accumulation by reducing hepcidin transcription, thereby leading to HCC development. This study investigated whether long-term treatment with BCAA reduced hepatic iron accumulation and oxidative stress in iron-overloaded HCVTgM and in patients with HCV-related advanced fibrosis. METHODS: Male HCVTgM were fed an excess-iron diet that comprised either casein or 3.0% BCAA, or a control diet, for 6 months. RESULTS: For HCVTgM, BCAA supplementation increased the serum hepcidin-25 levels and antioxidant status [ratio of biological antioxidant potential (BAP) relative to derivatives of reactive oxygen metabolites (dROM)], decreased the hepatic iron contents, attenuated reactive oxygen species generation, and restored mitochondrial superoxide dismutase expression and mitochondrial complex I activity in the liver compared with mice fed the control diet. After 48 weeks of BCAA supplementation in patients with HCV-related advanced fibrosis, BAP/dROM and serum hepcidin-25 increased and serum ferritin decreased compared with the pretreatment levels. CONCLUSIONS: BCAA supplementation reduced oxidative stress by restoring mitochondrial function and improved iron metabolism by increasing hepcidin-25 in both iron-overloaded HCVTgM and patients with HCV-related advanced fibrosis. These activities of BCAA may partially account for their inhibitory effects on HCC development in cirrhosis patients.


Assuntos
Aminoácidos de Cadeia Ramificada/administração & dosagem , Proteínas Alimentares/administração & dosagem , Hepacivirus/metabolismo , Hepatite C/dietoterapia , Ferro/metabolismo , Cirrose Hepática/dietoterapia , Fígado/metabolismo , Estresse Oxidativo , Poliproteínas/metabolismo , Proteínas Virais/metabolismo , Idoso , Idoso de 80 Anos ou mais , Animais , Antioxidantes/metabolismo , Biomarcadores/sangue , Modelos Animais de Doenças , Feminino , Ferritinas/sangue , Hepacivirus/genética , Hepatite C/sangue , Hepatite C/genética , Hepatite C/metabolismo , Hepcidinas/sangue , Humanos , Japão , Cirrose Hepática/sangue , Cirrose Hepática/genética , Cirrose Hepática/metabolismo , Masculino , Camundongos Transgênicos , Poliproteínas/genética , Espécies Reativas de Oxigênio/sangue , Fatores de Tempo , Resultado do Tratamento , Proteínas Virais/genética
2.
Plant Biotechnol J ; 12(6): 734-42, 2014 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24605946

RESUMO

We have increased the productivity and yield of potato (Solanum tuberosum) by developing a novel method to enhance photosynthetic carbon fixation based on expression of a polyprotein (DEFp) comprising all three subunits (D, E and F) of Escherichia coli glycolate dehydrogenase (GlcDH). The engineered polyprotein retained the functionality of the native GlcDH complex when expressed in E. coli and was able to complement mutants deficient for the D, E and F subunits. Transgenic plants accumulated DEFp in the plastids, and the recombinant protein was active in planta, reducing photorespiration and improving CO2 uptake with a significant impact on carbon metabolism. Transgenic lines with the highest DEFp levels and GlcDH activity produced significantly higher levels of glucose (5.8-fold), fructose (3.8-fold), sucrose (1.6-fold) and transitory starch (threefold), resulting in a substantial increase in shoot and leaf biomass. The higher carbohydrate levels produced in potato leaves were utilized by the sink capacity of the tubers, increasing the tuber yield by 2.3-fold. This novel approach therefore has the potential to increase the biomass and yield of diverse crops.


Assuntos
Oxirredutases/metabolismo , Fotossíntese , Tubérculos/crescimento & desenvolvimento , Poliproteínas/metabolismo , Proteínas Recombinantes/metabolismo , Solanum tuberosum/genética , Metabolismo dos Carboidratos , Escherichia coli/enzimologia , Metaboloma , Fenótipo , Folhas de Planta/metabolismo , Tubérculos/metabolismo , Plantas Geneticamente Modificadas , Plastídeos/metabolismo , Subunidades Proteicas/metabolismo
3.
Antiviral Res ; 88(1): 95-106, 2010 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-20705106

RESUMO

Hepatitis C virus (HCV) infection is a common cause of chronic liver disease and a serious threat to human health. The HCV NS3/4A serine protease is necessary for viral replication and innate immune evasion, and represents a well-validated target for specific antiviral therapy. We previously reported the isolation of single-chain antibodies (scFvs) that inhibit NS3/4A protease activity in vitro. Expressed intracellularly (intrabodies), these scFvs blocked NS3-mediated proliferation of NS3-transfected cells. Here we show that anti-NS3 scFvs suppress HCV RNA replication when expressed intracellularly in Huh7 hepatoma cells bearing either subgenomic or genome-length HCV RNA replicons. The expression of intrabodies directed against NS3 inhibited the autonomous amplification of HCV replicons resistant to small-molecule inhibitors of the NS3/4A protease, and replicons derived from different HCV genotypes. The combination of intrabodies and interferon-α had an additive inhibitory effect on RNA replication in the replicon model. Intrabody expression also inhibited production of infectious HCV in a cell culture system. The NS3 protease activity was inhibited by the intrabodies in NS3-expressing cells. In contrast, cell-free synthesis of HCV RNA by preformed replicase complexes was not inhibited by intrabodies, suggesting that the major mode of inhibition of viral replication is inhibition of NS3/4A protease activity and subsequent suppression of viral polyprotein processing.


Assuntos
Hepacivirus , Inibidores de Proteases/farmacologia , Anticorpos de Cadeia Única/imunologia , Anticorpos de Cadeia Única/uso terapêutico , Proteínas não Estruturais Virais/imunologia , Anticorpos Antivirais/imunologia , Antivirais/farmacologia , Antivirais/uso terapêutico , Linhagem Celular , Avaliação Pré-Clínica de Medicamentos , Quimioterapia Combinada , Ensaio de Imunoadsorção Enzimática , Imunofluorescência , Hepacivirus/efeitos dos fármacos , Hepacivirus/genética , Hepacivirus/imunologia , Hepacivirus/fisiologia , Humanos , Interferon-alfa/farmacologia , Interferon-alfa/uso terapêutico , Plasmídeos , Reação em Cadeia da Polimerase , Poliproteínas/metabolismo , RNA Viral/genética , RNA Polimerase Dependente de RNA , Replicon/efeitos dos fármacos , Proteínas não Estruturais Virais/genética , Replicação Viral/efeitos dos fármacos , Replicação Viral/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA